Neuromuscular Junction Transmission Failure in Sarcopenia
CEO, Thomas Holm Pedersen, PhD, NMD Pharma, Aarhus, (Denmark).
Investigating ClC-1 chloride channel inhibition as a therapeutic strategy for sarcopenia.
See the ICFSR program here:
NMD Pharma at ICFSR 2022 - Symposium 4 - Part 3
Previous
Previous
NMD Pharma at ICFSR 2022 - Symposium 4 - Part 2
Next
Next